Can-Fite BioPharma Past Earnings Performance
Past criteria checks 0/6
Can-Fite BioPharma's earnings have been declining at an average annual rate of -1.1%, while the Biotechs industry saw earnings growing at 12% annually. Revenues have been declining at an average rate of 37.4% per year.
Key information
-1.1%
Earnings growth rate
58.3%
EPS growth rate
Biotechs Industry Growth | -24.5% |
Revenue growth rate | -37.4% |
Return on equity | -122.3% |
Net Margin | -1,027.5% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year
Jun 19Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?
Jun 30We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate
Mar 08Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?
Nov 21Can-Fite BioPharma (TLV:CANF) Will Have To Spend Its Cash Wisely
May 16We're A Little Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate
Jan 31Revenue & Expenses Breakdown
How Can-Fite BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | -8 | 3 | 6 |
30 Sep 23 | 1 | -9 | 3 | 7 |
30 Jun 23 | 1 | -10 | 3 | 8 |
31 Mar 23 | 1 | -10 | 3 | 8 |
31 Dec 22 | 1 | -10 | 3 | 8 |
30 Sep 22 | 1 | -14 | 3 | 8 |
30 Jun 22 | 1 | -15 | 4 | 9 |
31 Mar 22 | 1 | -16 | 4 | 10 |
31 Dec 21 | 1 | -15 | 4 | 10 |
30 Sep 21 | 1 | -12 | 4 | 10 |
30 Jun 21 | 1 | -11 | 3 | 9 |
31 Mar 21 | 1 | -12 | 3 | 9 |
31 Dec 20 | 1 | -15 | 3 | 12 |
30 Sep 20 | 1 | -13 | 3 | 13 |
30 Jun 20 | 2 | -17 | 3 | 14 |
31 Mar 20 | 2 | -13 | 3 | 13 |
31 Dec 19 | 2 | -13 | 3 | 11 |
30 Sep 19 | 2 | -11 | 3 | 9 |
30 Jun 19 | 4 | -8 | 3 | 7 |
31 Mar 19 | 3 | -7 | 3 | 6 |
31 Dec 18 | 4 | -7 | 3 | 6 |
30 Sep 18 | 4 | -5 | 3 | 6 |
30 Jun 18 | 2 | -6 | 3 | 5 |
31 Mar 18 | 1 | -5 | 3 | 5 |
31 Dec 17 | 1 | -6 | 3 | 5 |
30 Sep 17 | 1 | -6 | 3 | 6 |
30 Jun 17 | 0 | -9 | 3 | 6 |
31 Mar 17 | 0 | -7 | 3 | 7 |
31 Dec 16 | 0 | -8 | 3 | 6 |
30 Sep 16 | 0 | -5 | 3 | 6 |
30 Jun 16 | 0 | -6 | 3 | 5 |
31 Mar 16 | 0 | -6 | 3 | 4 |
31 Dec 15 | 0 | -6 | 3 | 4 |
30 Sep 15 | 0 | -7 | 3 | 3 |
30 Jun 15 | 0 | -5 | 3 | 3 |
31 Mar 15 | 0 | -5 | 3 | 4 |
31 Dec 14 | 0 | -6 | 3 | 4 |
30 Sep 14 | 0 | -7 | 4 | 5 |
30 Jun 14 | 0 | -8 | 4 | 5 |
31 Mar 14 | 0 | -8 | 5 | 4 |
31 Dec 13 | 0 | -8 | 5 | 4 |
Quality Earnings: CANF is currently unprofitable.
Growing Profit Margin: CANF is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CANF is unprofitable, and losses have increased over the past 5 years at a rate of 1.1% per year.
Accelerating Growth: Unable to compare CANF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CANF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: CANF has a negative Return on Equity (-122.28%), as it is currently unprofitable.